期刊文献+

艾司西酞普兰与文拉法辛治疗抑郁障碍的成本-效果分析 被引量:3

Analysis of the Effect of Ai Sciplan and Vin Rafa Sin in the Treatment of Depressive Disorder Cost
原文传递
导出
摘要 目的对常用的抗抑郁药物艾司西酞普兰与文拉法辛治疗抑郁障碍进行成本-效果分析。方法将78例符合《中国精神障碍分类与诊断标准》(第三版)抑郁发作诊断标准的抑郁障碍患者随机分为两组,分别给予艾司西酞普兰或文拉法辛治疗8周,观察两组治疗方案的疗效及安全性,运用药物经济学的成本-效果分析方法进行评价。结果艾司西酞普兰、文拉法辛组治疗药品成本分别为663.04元和1164.80元;有效率分别为82.05%和84.62%;不良反应发生率分别为30.77%和28.21%。结论根据药物经济学评价,艾司西酞普兰组优于文拉法辛组。 Objective To commonly used antidepressant escitalopram and Vin Rafa Sin in the treatment of depression for cost-effectiveness analysis. Methods 78 patients with"Chinese classification and diagnostic criteria of mental disorders (Third Edition)"in patients with depressive disorder were randomly divided into depression diagnosis standard into two groups,were treated with escitalopram and venlafaxine in the treatment of 8 weeks, to observe the safety and efficacy of treatment group two, using the pharmacoeconomic cost-effectiveness analysis. Result Escitalopram, venlafaxine group therapy drug costs were 663.04 yuan and 1164.80 yuan; the effective rates were 82.05% and 84.62%; the incidence of adverse reaction was 30.77% and 28.21% respectively. Conclusion On the basis of pharmacoeconomic evaluation, escitalopram group was better than that of venlafaxine group.
出处 《中国药物经济学》 2013年第4期16-18,共3页 China Journal of Pharmaceutical Economics
关键词 抑郁障碍 抗抑郁药 药物经济学 成本-效果分析 Depressive disorder Antidepressant Pharmacoeconomic Cost-effectiveness analysis
  • 相关文献

参考文献4

二级参考文献3

共引文献463

同被引文献24

  • 1许德河,孙颖.抗抑郁药治疗抑郁症的成本-效果分析[J].中国药业,2006,15(17):53-54. 被引量:2
  • 2赵靖平,翟金国,陈晋东,等.抑郁症和精神分裂症的疾病负担研究.中华医学会精神病学分会第七届学术年会论文摘要集[C].2006:2. 被引量:2
  • 3Bland RC. Epidemiology of affective disorder: a review. Can J Psy- chiatry, 1997, 42(4): 367. 被引量:1
  • 4Annemans L, Brignone M, Druais S, et al. Cost-Effectiveness Analysis of Pharmaceutical Treatment Options in the First- Line Management of Major Depressive Disorder in Belgium. PharmacoEconornics, 2014, 32(5): 479-493. 被引量:1
  • 5Ramsberg J, Asseburg C, Henriksson M. Effectiveness and cost- effectiveness of antidepressants in primary care a multiple treatment comparison meta-analysis and cost-effectiveness model. PLoS One, 2012, 7(8): e42003. 被引量:1
  • 6World Health Organization. Fact sheet N369[EB/OL]. http://www. who.int/mediacentre/factsheets/fs369/en/,2012/2015-02-06. 被引量:1
  • 7Annemans L, Brignone M, Druais S.Cost-effeetiveness analysis of pharmaceutical treatment options in the first-line management of major depressive disorder in Belgium [J]. PharmacoEeonomies, 2014,32(5) :479-93. 被引量:1
  • 8Demyttenaere K, Hemels ME, Hudry J, ~. A cost-effectiveness model of escitalopram, eitalopram,and venlafaxine as first-line treatment for major depressive disorder in Belgium [J].Clinical Therapeutics, 2005,27(1) : 111-24. 被引量:1
  • 9Wessling A, Ramsberg J.The review of antidepressants: the Den- tal and Pharmaceutical Bene?ts Agency.Solna:TLV.2008. 被引量:1
  • 10翟金国,赵靖平,陈敏,苏中华.山东省某地区抑郁症患者的经济花费调查[J].中国神经精神疾病杂志,2008,34(3):165-168. 被引量:17

引证文献3

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部